Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK AS25-adjuvanted influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The GSK AS25-adjuvanted influenza vaccine (GSK576389A, FluAS25) is an investigational inactivated biologic vaccine developed by GSK for the prevention of seasonal influenza, specifically targeting elderly adults (≥65 years). The vaccine contains haemagglutinin (HA) antigens from inactivated influenza virus strains and utilizes GSK's proprietary AS25 adjuvant system to enhance immunogenicity in the aging immune system. It has been evaluated in Phase II clinical trials (e.g., NCT00633074) comparing thiomersal-free and thiomersal-reduced formulations to assess safety and haemagglutination-inhibition (HI) antibody responses.
- Other names
- GSK AS25-adjuvanted influenza vaccinethiomersal-free AS25-adjuvanted influenza vaccinethiomersal-reduced AS25-adjuvanted influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GSK AS25-adjuvanted influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK AS25-adjuvanted influenza vaccine.